The Munich-based biotech company reports an important strategic success: two new sales partnerships for Australia and Latin America bring the Eylea biosimilar FYB203 closer to global markets. After the spectacular agreement with Regeneron a few weeks ago, Formycon is continuing its aggressive expansion strategy. But is that enough to compensate for the dramatic price losses of the past few months?
Strategic partnerships: The key to success
Yesterday evening, Formycon announced two crucial deals through its license partner Klinge Biopharma:
- Australia: Partnership with Actor Pharmaceuticals for the entire continent
- Latin America: Agreement with Megalabs SA for key markets in the region
- Revenue model: Formycon will receive a percentage interest in the mid-single-digit to low double-digit range
These agreements follow the company’s tried-and-tested pattern: Instead of building up expensive sales structures of its own, the company relies on established regional partners with a strong market presence. This minimizes risks and significantly speeds up market access.
After Regeneron agreement: USA, Australia, Latin America conquered
Yesterday’s success builds on the spectacular coup of October 2nd. At that time, Formycon ended the tough patent dispute with the US giant Regeneron – and thereby secured access to the most lucrative market in the world. FYB203 can attack in the USA by the fourth quarter of 2026 at the latest.
The expansion to Australia and Latin America shows that Formycon is pursuing its global ambitions with iron determination. The Eylea biosimilar is expected to be present in all major markets.
Quarterly figures as the next litmus test
The Q3 figures are due on November 13th. While the new partnerships will only become noticeable in later quarters, analysts expect important signals about ongoing business development.
Despite a difficult year on the stock market with a price drop of over 60 percent since the annual high, the share price is stabilizing. The successful implementation of the marketing strategy could be the decisive turning point.
Advertisement
Formycon share: buy or sell?! New Formycon analysis from October 18th provides the answer:
The latest Formycon figures speak for themselves: there is an urgent need for action for Formycon shareholders. Is it worth getting started or should you sell? In the current free analysis from October 18th you will find out what to do now.
Formycon: Buy or sell? Read more here…
